[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elevated-blood-pressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elevated-blood-pressure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,81,114,145,179,208,238,269,299,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100462134","office-home-and-ambulatory-blood-pressure-100462134",false,"NCT05297708","Office, Home, and Ambulatory Blood Pressure","Office, Home, and Ambulatory Blood Pressure Measurements in Pediatric Patients","HBPA","Inclusion Criteria:\n\n1. Age 6 years to \\\u003C19 years old;\n2. Elevated blood pressure defined as 15% lower than the 95%ile BP based on clinical practice guidelines(CPG) but less than stage II hypertension based on CPG;\n3. Tolerate ABPM 24 hours;\n4. Tolerate HBP; and\n5. Can have diabetes mellitus, obstructive sleep apnea, and attention deficit hyperactivity disorder managed by medication.\n6. On stable doses of medications known to affect BP such as:\n\n   1. Corticosteroids\n   2. Calcineurin inhibitors\n   3. Oral decongestants;\n7. Clinically stable\n\nExclusion Criteria:\n\n1. On antihypertension medications or treated in the last 6 months;\n2. Pregnant;\n3. Structural heart disease such as:\n\n   1. Obstructive valvular disease\n   2. Coarctation of the aorta\n   3. Cardiomyopathy;\n4. Other secondary causes such as:\n\n   1. Renal artery stenosis\n   2. Neurological condition with dysautonomia;\n5. Recent initiation of medications known to affect BP such as:\n\n   1. Corticosteroids\n   2. Calcineurin inhibitors\n   3. Oral decongestants;","ALL","6 Years","19 Years",{"count":21,"type":22},52,"ESTIMATED","OBSERVATIONAL","This will be a prospective observational study. The population would be pediatric patients 6 years to \\\u003C19 years of age who were referred for elevated blood pressure to investigate if home blood pressure (HBP) can determine blood pressure phenotype (normotensive, hypertensive, masked hypertension, white coat hypertension) as accurately as ambulatory blood pressure monitor (ABPM) in childhood and adolescence.",[26],"Elevated Blood Pressure","RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2022-03-24",{"date":35,"type":22},"2028-01-01",{"name":37,"class":38},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100642424","feasibility-of-a-community-integrated-isometric-handgrip-exercise-program-and-its-preliminary-effects-on-blood-pressure-and-cognitive-function-in-older-adults-100642424","NCT07648498","Feasibility of a Community-Integrated Isometric Handgrip Exercise Program and Its Preliminary Effects on Blood Pressure and Cognitive Function in Older Adults","Inclusion Criteria:\n\n* 65 years of age or older\n* Currently attending the Physical Activity Centre of Excellence at McMaster University\n* English speaking\n* Diagnosed with hypertension or elevated blood pressure\n\nExclusion Criteria:\n\n* Current or prior participation in chronic isometric exercise\n* Unstable angina.\n* Uncontrolled hypertension\n* Uncontrolled heart failure and\u002For arrhythmias\n* Recent myocardial infarction or electrocardiography changes\n* Complete heart block\n* Carpal tunnel syndrome\n* Arthritis that may be aggravated by handgrip exercise\n* Changes to the type and\u002For dose of blood pressure medications within 3 months of starting the study.","65 Years",{"count":48,"type":22},30,"INTERVENTIONAL",[51],"NA","The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function.\n\nThe main questions it aims to answer are:\n\n* Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting?\n* Does participation in the program lead to changes in blood pressure and cognitive function?\n\nResearchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes.\n\nParticipants will:\n\n* Be randomly assigned to use one of two handgrip devices.\n* Complete supervised exercise sessions twice per week for 4 weeks.\n* Perform brief handgrip contractions at a set intensity during each session.\n* Complete blood pressure and cognitive assessments before and after the program.",[54,26],"Hypertension",[56,57,54,58,59,60,61,62,63,64,65,66,67,68,69],"Older Adults","Isometric Handgrip Exercise","Feasibility","Cognition","Exercise Intervention","Blood Pressure","Community-based exercise","Pilot study","Aging","Acceptability","Handgrip training","Isometric Exercise","Cognitive function","Cardiovascular health","NOT_YET_RECRUITING","2026-06-11",{"date":73,"type":31},"2026-06-15",{"date":75,"type":22},"2026-07-28",{"date":77,"type":22},"2026-09-15",{"name":79,"class":38},"McMaster University",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":49,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100643456","phase-1-hjb647-phase-1b-study-in-japanese-healthy-participants-with-elevated-blood-pressure-and-patients-with-hypertension-100643456","NCT07644364","HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension","A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HJB647 Following Single Ascending Dose and Up-titration Multiple Dose Administration in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension","Inclusion Criteria:\n\n* Japanese healthy participants with elevated blood pressure (Part 1) and patients with mild-to-moderate hypertension (Part 2)\n* Age: 18 to 55 years (Part 1) and 18 to 60 years (Part 2)\n* Body weight:\n\n  * Male: ≥ 50.0 kg\n  * Female: ≥ 45.0 kg\n* Body Mass Index (BMI): 18.0 to 30.0 kg\u002Fm²\n* Axillary body temperature: 35.0-37.5 °C\n* Heart rate: 50-90 bpm\n* Blood pressure criteria are as follows:\n\n  * Part 1: Healthy Participants with Elevated Blood Pressure Screening: Systolic Blood Pressure (SBP): 120 ≤ SBP ≤ 139 mmHg; Diastolic Blood Pressure (DBP): 60 ≤ DBP ≤ 94 mmHg Baseline (Day -1): SBP: 120 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg\n  * Part 2: Patients with Hypertension Screening and Baseline (Day -1): SBP: 140 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg\n\nExclusion Criteria:\n\n* Significant illness, including infectious diseases that have not resolved within 30 days prior to baseline\n* History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as:\n\n  * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker.\n  * History of familial long QT syndrome or known family history of Torsades de Pointes\n  * Resting QT interval corrected by Fridericia's formula (QTcF) ≥ 450 msec (male) or ≥ 460 msec (female) at screening\n* At screening, hypokalemia or hypomagnesemia defined as potassium or magnesium values below the LLN on repeat measurement, or laboratory abnormalities indicating hypothyroidism, as determined at the discretion of the investigator\n* HbA1c ≥ 7.0% or LDL cholesterol ≥ 180 mg\u002FdL or triglycerides ≥ 250 mg\u002FdL\n* Use of any prescription drugs or herbal supplements within 4 weeks prior to initial dosing, and\u002For OTC medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing\n* Women of childbearing potential\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply",true,"18 Years","55 Years",{"count":92,"type":22},74,[94],"PHASE1","The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647",[26,54],[98,99,100,101,102,103],"HJB647","safety","tolerability","pharmacokinetics","Japanese participants with elevated blood pressure","Japanese patients with hypertension","2026-06-08",{"date":106,"type":31},"2026-06-12",{"date":108,"type":22},"2026-06-23",{"date":110,"type":22},"2027-01-20",{"name":112,"class":113},"Novartis Pharmaceuticals","INDUSTRY",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":49,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":39},"100624744","the-acute-effect-of-exercise-type-and-timing-on-ambulatory-blood-pressure-and-intra-ocular-pressure-in-individuals-with-glaucoma-the-achieve-project-100624744","NCT07413614","The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).","The ACHIEVE-project: Advancing Cardiovascular and Ocular Health In Eye Patients. The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma.","ACHIEVE","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Patients with POAG AND \\[elevated BP OR hypertension (Average SBP on office BP and Home BP ≥120 mmHg AND\u002FOR Average DBP on office BP and Home BP ≥70 mmHg 26) with or without the use of anti-hypertensive medication\\]\n* Patients without recent changes in medication and glaucoma care within the past four weeks.\n\nExclusion Criteria:\n\n* Not able to provide informed consent\n* SBP and\u002For DBP are ≥ 150 mmHg and\u002For ≥ 95 mmHg, respectively, on office BP at screening AND on home BP measurement conducted in the week following screening (to identify White Coat Hypertension) to ensure safety. These patients require referral for early treatment.\n* Aberrant cardiopulmonary exercise test (CPET) at screening (Life-threatening arrhythmias, ischemia,…)\n* Unable to perform one or more of the four exercise sessions due to physical and or mental limitations (severe lung disease, musculoskeletal issues, unstable angina,…)\n* Severe osteoarthritis pending knee replacement surgery (these patients may be unable to perform the IRE (i.e. wall squat exercise)\n* Unable to communicate in Dutch\n* Active malignancy\n* Participation in an interventional Trial with an investigational medicinal product (IMP), exercise intervention or device\n* Unwillingness to repeat ABPM\n* Relative contraindications to ABPM: diagnosed atrial fibrillation, nighttime workers, occupational drivers",{"count":123,"type":22},60,[51],"ACHIEVE aims to determine whether exercise can be a safe and effective non-drug approach to improve blood pressure control in patients with primary open-angle glaucoma (POAG). Although exercise is a promising and potentially well-accepted therapy, its use in clinical care is limited because the safety and effectiveness of different exercise types (aerobic, isometric, moderate, or high intensity) and timing (morning versus evening) have not been systematically studied in people with POAG and elevated blood pressure.\n\nThis study will evaluate the safety and short-term effects of different exercise modalities and timings on 24-hour ambulatory blood pressure and blood pressure variability in patients with POAG and elevated blood pressure.\n\nIt is hypothesized that:\n\n* Each exercise session will lead to a temporary reduction in blood pressure (post-exercise hypotension).\n* The greatest and longest-lasting reduction will occur after high-intensity aerobic exercise performed in the morning.\n\nIt is also expected that all exercise types and timings will be safe for participants.",[127,54,26],"Glaucoma Open-Angle Primary",[129,130,67,131,132,133,54,134,135],"Ambulatory blood pressure","High intensity interval training","Intra-ocular pressure","Moderate continuous training","Primary open angle glaucoma","Blood pressure variability","Exercise","2026-02-09",{"date":138,"type":31},"2026-02-17",{"date":140,"type":22},"2026-04",{"date":142,"type":22},"2027-03",{"name":144,"class":38},"KU Leuven",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":88,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":49,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":39},"100623524","sodium-rich-condiments-unifying-health-and-taste-100623524","NCT07397754","Sodium-rich COndiments Unifying Health and Taste","Scout","Inclusion Criteria:\n\n1. ≥ 50, \\\u003C 75 years old\n2. Male or postmenopausal female (self-reported)\n3. ≥ 50 kg body weight\n4. Systolic blood pressure (≥ 130, \\\u003C 160 mmHg) or diastolic blood pressure (≥ 85, \\\u003C 100 mmHg)\n5. Willing and able to follow intervention protocol\n6. Ability to identify basic tastes (determined by taste discrimination test)\n7. English speaking\n\nExclusion Criteria:\n\n1. Prescribed and taking medication which may affect study outcomes (i.e. for blood pressure management, blood thinning etc.) in consultation with study physician (Prof Melvin Leow) and PI(Dr Darel Toh)\n2. Type 1 or type 2 diabetes mellitus (i.e. fasting blood glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5 %)\n3. Taking dietary supplements which may affect study outcomes one month prior to their first visit in consultation with study physician, PI and study team\n4. Obesity (BMI ≥ 27.5 kg\u002Fm2)\n5. History or known present diagnosis of hematological (G6PD and coagulation disorders), hepatic (hepatitis B and C), renal, gastrointestional or other relevant disease \u002F disorders which may affect the outcomes of interest in consultation with study physician, PI and study team\n6. History of arteriovenous shunt or mastectomy\n7. Women who are pregnant, lactating or planning pregnancy\n8. History or present diagnosis of HIV and\u002For tuberculosis\n9. History of severe vasovagal syncope (blackouts or near faints) following blood draw\n10. Drug abuse within last 5 years\n11. Excessive alcoholic beverage consumption \\> 2 servings per day (1 serving defined as 360 mL beer, 150 mL wine or 45 mL distilled spirits)\n12. Smoking (cigarette, e-cigarette, cigar, pipe, vape)\n13. Engaging in habitual vigorous physical activity (as defined by physical activity questionnaire-PAR)\n14. Allergic or intolerance to intervention foods.\n15. Dislike or unwilling to consume intervention foods\n16. Photophobic (sensitivity to intense lights and colours), particularly to intense red lights\n17. Has sinus problems problems that affect taste and smell\n18. Involvement in other clinical studies that may influence the outcome of the study\n19. An ASTAR Staff.\n20. A study team member or their immediate family member","50 Years","75 Years",{"count":155,"type":22},32,[51],"This research aims to develop an evidence-based classification for sodium-rich condiments (natremic index) based on their CVD-related risks. It is hypothesised that the acute cardiovascular and physiological response (effectively extrapolated to long-term CVD risks) to meals prepared with various sodium-rich condiments can be leveraged upon for the development of such an index that will systematically classify sodium-rich condiments based on the risk they present to cardiovascular health.",[26,159,160],"Vascular Health","Sensory Evaluation",[162,163,164,165,166,167,168,169],"sodium intake","natremic index","elevated blood pressure","cardiometabolic outcomes","condiments","Asian","vascular health","sensory evaluation","2026-02-05",{"date":136,"type":31},{"date":173,"type":31},"2025-09-22",{"date":175,"type":22},"2026-09-22",{"name":177,"class":178},"Singapore Institute of Food and Biotechnology Innovation","OTHER_GOV",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":186,"minAge":187,"maxAge":152,"enrollmentInfo":188,"targetDuration":4,"studyType":49,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":39},"100545047","no-time-to-pause-physical-activity-to-improve-health-of-midlife-hispanic-women-100545047","NCT06376812","No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women","No Time to Pause: Physical Activity to Improve Health and Well-being of Midlife Hispanic Women During the Menopausal Transition","Inclusion Criteria:\n\n1. Female\n2. Hispanic by self-report\n3. Able to speak and read English\n4. Sedentary\n5. Age 45-50\n6. Diagnosed with elevated blood pressure or objectively measured systolic blood pressure 120-139 mmHg and\u002For diastolic blood pressure 80-89 mmHg averaged from ≥ 2 measures on ≥ 2 outpatient visits\n7. Symptoms consistent with the menopause transition (persistent difference of ≥7 days in the length of consecutive cycles; persistence is defined as recurrence within 10 cycles of the first variable length cycle)\n8. Apparently healthy\n9. Self-reported ability to engage in moderate intensity physical activity\n10. Access to a smart device that is compatible with a Fitbit application\n\nExclusion Criteria:\n\n1. Self-reported physical activity of ≥150 minutes per week\n2. Answered yes to any question on the Physical Activity Readiness (PAR-Q+) questionnaire\n3. Post-menopausal (12-months without a menstrual cycle)\n4. Diagnosed hypertension\n5. Cardiovascular, respiratory, neurological, renal, endocrine, gastrointestinal and\u002For psychiatric diseases, or any cancers\n6. Previous hysterectomy, oophorectomy, and\u002For uterine ablation\n7. Medication to treat hypertension, elevated glucose, cholesterol, depression, anxiety, and insomnia\n8. Hormonal medication via any route or implants\n9. Tamoxifen\n10. Pregnant, planning to become pregnant, or breastfeeding\n11. Planning to move out of the Galveston\u002FHouston area in the next 18 months\n12. Current participation in another physical activity study or program","FEMALE","45 Years",{"count":189,"type":22},40,[51],"This study will test the effects of a physical activity intervention among midlife Hispanic women.",[26,193],"Perimenopause",[195,196,197,198,199],"Physical activity","Women's health","Minority health","Behavior change","Hypertension prevention","2025-12-01",{"date":202,"type":31},"2025-12-08",{"date":110,"type":22},{"date":205,"type":22},"2029-01",{"name":207,"class":38},"The University of Texas Medical Branch, Galveston",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":49,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":39},"100584635","groceries-for-residents-of-southeastern-usa-to-stop-hypertension-100584635","NCT06891911","Groceries for Residents of Southeastern USA to Stop Hypertension","GoFreshSE","Inclusion Criteria:\n\n1. Resting systolic blood pressure of 120 to \\\u003C160 mm Hg and diastolic blood pressure \\\u003C110 mm Hg\n2. Resident of Florida, Georgia, and Tennessee\n3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period\n4. Have access to refrigeration, cooking appliances, and Wi-Fi\u002Fcellular service\n5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send\u002Freceive text messages\n6. Willing and able to complete required measurement procedures\n7. Able to provide consent for the study\n8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study\n\nExclusion Criteria:\n\nA. Laboratory Exclusions:\n\n1. Serum potassium ≥5.0 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n2. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin per 1.73 m\\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n3. Hemoglobin A1c ≥6.5%\n\nB. Medication Exclusions:\n\nUnstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following:\n\n1. GLP-1 and dual GLP-1\u002FGIP receptor agonists\n2. Anti-hypertension medications\n3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors\n4. Glucose lowering medications\n\nUse of any of the following medications:\n\n1. Potassium supplement, except if part of a multivitamin\n2. Warfarin (Coumadin)\n3. Chronic oral corticosteroid (intermittent use is okay)\n4. Weight loss medications (non-GLP-1 receptor agonists)\n5. Sulfonylurea or any insulin use\n\nAny medication not compatible with participation as determined by the investigators\n\nC. Physical Exclusions:\n\n1. Systolic blood pressure: \\\u003C120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg\n2. Arm circumference \\>52 cm (or the upper limit of the validated BP device)\n\nD. Medical History Exclusions:\n\n1. Self-reported weight loss or gain of 15 pounds during prior 2 months\n2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission\n3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)\n4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence\n5. Pregnancy or lactation or planned pregnancy during the study period\n6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months\n7. Hypoglycemia hospitalization in the last 12 months\n8. Any other serious illness or condition not compatible with participation as determined by the investigators\n\nE. Lifestyle and Other Exclusions:\n\n1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence\n2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week\n3. Active substance use disorder that would interfere with participation\n4. Extreme food insecurity\n5. Participation in or planning to start weight loss program\n6. Current participation in another clinical trial that could interfere with the study protocol\n7. Anticipated change in residence outside of eligible states prior to the end of the study\n8. Families with more than 6 adults at dinner time (children count as half an adult)\n\nF. Investigator discretion",{"count":216,"type":22},150,[51],"GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.",[54,26,220,221],"Cardiovascular Diseases","Dietary Intervention",[54,223,224,225,226,227,228],"Dash Diet","Low Sodium","Diet","Nutrition","Clinical trial","Dietitian","2025-10-27",{"date":231,"type":31},"2025-10-28",{"date":233,"type":31},"2025-10-14",{"date":235,"type":22},"2026-06",{"name":237,"class":38},"Beth Israel Deaconess Medical Center",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":244,"maxAge":153,"enrollmentInfo":245,"targetDuration":4,"studyType":49,"phases":247,"briefSummary":248,"conditions":249,"keywords":254,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":39},"100573937","wearable-technology-data-driven-digital-health-coaching-activation--a-mixed-methods-study-100573937","NCT06752772","WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study","Inclusion Criteria:\n\n* 21-75 years old\n* Patients who are at risk of any of the following:\n\n  1. Elevated blood pressure\n  2. Overweight (BMI\\>=23kg\u002Fm2)\n  3. Pre-diabetes, OR\n* Patients who have one or more of the following (HOLD) conditions:\n\n  1. Hypertension\n  2. Obesity (BMI\\>=27.5kg\u002Fm2)\n  3. HyperLipidemia\n  4. Type 2 Diabetes Mellitus\n* Patients who own a smartphone\n* Patients who are willing to wear a smartwatch during the intervention period.\n\nExclusion Criteria:\n\n* Patients who have a medical condition that prevented participation in physical activity\n* Patients who have current diagnosis or history of eating disorder, depression\n* Patients who are currently pregnant or planning to become pregnant in the next 6 months\n* Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study)\n* Patients who are on weight loss medications (over-the-counter or prescription)\n* Patients who are not mentally-, physically- or technologically-capable\n* Patients who is unable to provide informed consent.","21 Years",{"count":246,"type":22},1700,[51],"Public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. Despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. In Singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. Metabolic syndrome (MetS), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. Disparities exist in the delivery of lifestyle interventions among healthcare providers (HCPs), with many patients receiving inadequate guidance. Digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. Challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.",[26,54,250,251,252,253],"Overweight\u002FObesity","Type 2 Diabetes Mellitus (T2DM)","Hyperlipidemia","Prediabetes",[255,256,257,258,259],"Digital Health Intervention","Health Coaching","Personalisation","Nudging","Wearables","2025-09-29",{"date":262,"type":31},"2025-10-02",{"date":264,"type":31},"2024-08-06",{"date":266,"type":22},"2026-02",{"name":268,"class":38},"Alexandra Hospital",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":88,"sex":17,"minAge":275,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":49,"phases":278,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":39},"100515508","know-your-pressures-nyc-100515508","NCT05992415","Know Your Pressures NYC","Inclusion Criteria:\n\n* Individuals age 40 and older.\n* Living independently in an affordable housing development.\n* Have a cell phone that can receive and send text messages (SMS).\n\nExclusion Criteria:\n\n* Self-reported terminal illness with life expectancy less than 1 year.\n* Inability to provide informed consent due to dementia or other reasons.","40 Years",{"count":277,"type":22},7085,[51],"Dr. Lisa A. Hark (PI and Study Chair) and an interdisciplinary team have designed \"Know Your Pressures NYC\" to conduct blood pressure (BP)\u002Fglaucoma screenings in adults age 40+ to identify undiagnosed and\u002For uncontrolled hypertension and\u002For glaucoma\u002Fsuspect. For the purpose of this study, individuals will be identified as glaucoma suspects if they have elevated intraocular pressure (IOP) or have features of glaucoma optic neuropathy, as assessed by optical coherence tomography (OCT) and fundus\u002Foptic nerve photographs, as interpreted by the masked Reading Center.",[281,54,282,26],"Glaucoma","Glaucoma, Suspect",[284,285,286,287,288,289,290],"Blood pressure (BP)","Intraocular pressure (IOP)","Optic nerve imaging","Fundus photography","Blood pressure and glaucoma screening","Optical coherence tomography (OCT)","Hypertension (HTN)","2025-09-17",{"date":173,"type":31},{"date":294,"type":22},"2026-07-01",{"date":296,"type":22},"2031-06-30",{"name":298,"class":38},"Columbia University",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":305,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":49,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":321},"100580920","a-pivotal-study-to-evaluate-the-effectiveness-of-isometric-handgrip-therapy-in-elevated-blood-pressure-and-hypertensive-subjects-100580920","NCT06843577","A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects","Inclusion Criteria:\n\n1. Subject is male or female age 22 or older\n2. Diagnosed with elevated blood pressure or hypertension and verified during Visit #1 by standardized seated cuff SBP\n3. Have not taken antihypertensive medication for ≥30 days prior to the SEPV\n4. Subject is expected to have sufficient vision, hearing, and hand strength (hand strength is demonstrated by a maximum voluntary contraction (MVC) equaling 35 units of force in both hands measured by a dynamometer\n5. Subject has baseline BP measurements collected and completes study device training during Baseline Assessment (Visit #1);\n6. Subject agrees to maintain non-use of medications and over-the-counter (OTC) supplement regimen related to hypertension throughout the treatment phase;\n7. Patient can comply with and agrees to complete all required study procedures, study clinic visits, and associated activities;\n8. Patient must be able to understand and give written informed consent in the language provided;\n9. Subject must have SBP of 130 to ≤149 mmHg, if subjects present with SBP reading of ≥140mmHg they will receive heightened monitoring throughout the first month of the study\n\nExclusion Criteria:\n\n1. Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to screening or barrier methods such as condom and spermicide in use at least 14 days prior to visit 1) or is pregnant, lactating, or plans to become pregnant during the study).\n2. BP ≥150 mmHg (systolic) and\u002For \\>90 mmHg (diastolic)\n3. A history of heart failure with current New York Heart Association (NYHA) class III- IV functional classification\n4. Currently has, or has had a history, of atrial fibrillation, in accordance with 2007 Heart Rhythm Society (HRS)\u002FEuropean Heart Rhythm Association (EHRA)\u002FEuropean Cardiac Arrhythmia Society (ECAS) guidelines\n5. Patient has experienced hospitalization due to a hypertensive emergency, with impending or progressive target organ dysfunction (i.e., renal dysfunction, left ventricular hypertrophy or CNS involvement) within the past six (6) months\n6. A \\>10 mmHg difference in seated cuff SBP between the right and left arms collected during the SEPV;\n7. Unstable BP, defined as \\>5 mmHg variance between any two (2) consecutive weekly readings (with a maximum of four (4) attempts) to determine a baseline BP measurement ;\n8. Arm circumference greater than 45 cm;\n9. Acute illness, infection, or inflammation\n10. Presence of any unstable cardiovascular disorder, such as MI, unstable angina, significant arrhythmia, stroke, or TIA; within the last six (6) months, or other serious comorbidity that would be likely to impact life expectancy to less than one (1) year or limit patient cooperation or study compliance;\n11. A history of rest or exertional angina pectoris in the previous six (6) months;\n12. History of solid organ transplant\n13. Any secondary form of hypertension (HTN) etiology, including but not limited to primary aldosteronism, chronic steroid therapy and Cushing syndrome, pheochromocytoma, aorta coarctation or untreated thyroid or parathyroid disease;\n14. Concurrent participation in an investigational clinical study that has not completed the follow-up period or planned participation in another study within the next six (6) months;\n15. Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete, good quality data or the completion of the research study;\n16. Patients who currently own or have owned another Zona Plus device and are, or have been, voluntarily performing the isometric handgrip activities.\n17. Subject plans for greater than 10% of body weight loss\u002Fgain (10% of body weight over a 6-month period) during the study","22 Years",{"count":307,"type":22},160,[51],"The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not currently taking antihypertensive medications. Half of the study subjects will also be randomized to record blood pressure at home throughout the study.",[26,54],[54,26],"2025-07-07",{"date":314,"type":31},"2025-07-10",{"date":316,"type":31},"2025-03-27",{"date":318,"type":22},"2027-05",{"name":320,"class":113},"Zona Health, Inc",5,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":330,"targetDuration":4,"studyType":49,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":39},"100588113","blood-pressure-following-isometric-exercise-in-inactive-adults-100588113","NCT06937164","Blood Pressure Following Isometric Exercise in Inactive Adults","Beliefs and Expectation Effects on Blood Pressure Following Isometric Exercise in Inactive Adults","BELIEF-BP","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-reported physically inactive or insufficiently active (not meeting current physical activity guidelines)\n* Not currently engaged in structured resistance or isometric exercise training\n* Able to attend lab sessions over a 4-week period\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Current diagnosis of hypertension requiring medication\n* Any known cardiovascular, neurological, or musculoskeletal condition contraindicating isometric exercise\n* Formal education or professional background in exercise science, physiology, or a related field\n* Pregnant or planning to become pregnant during the study period\n* Inability to follow verbal instructions or complete study protocols",{"count":331,"type":22},36,[51],"This study investigates how isometric exercise training (IET) affects blood pressure in physically inactive adults. Isometric exercise involves sustained muscle contractions without movement-for example, pushing against a fixed object. Previous research has shown that IET may help reduce blood pressure, but the mechanisms involved are not fully understood.\n\nThe purpose of this study is to assess both the immediate (acute) and long-term (chronic) effects of IET on cardiovascular outcomes. Participants will complete a series of lab-based exercise sessions over several weeks. In these sessions, they will perform repeated bouts of isometric leg extensions while seated on an exercise machine designed to measure muscle force.\n\nThroughout the study, researchers will monitor participants' blood pressure, heart rate, and muscle activity. Acute responses-such as post-exercise hypotension (a short-term drop in blood pressure)-will be measured immediately after exercise. Chronic changes, such as resting blood pressure improvements, will be evaluated across the training period.\n\nAdditional measurements will include heart rate variability (HRV), which gives insight into autonomic nervous system activity, and electromyography (EMG), which tracks muscle fatigue and activation patterns. These data will help explore potential mechanisms behind the cardiovascular benefits of IET.\n\nBy examining how repeated sessions of isometric exercise influence blood pressure and related physiological responses, this research may support the use of IET as a non-pharmacological strategy for managing or preventing hypertension in physically inactive individuals.",[54,26,335],"Sedentary Lifestlye",[67,61,337,338,339,340,341,342,60,343,344,345,328],"Post-Exercise Hypotension","Physical Inactivity","Heart Rate Variability","Electromyography (EMG)","Muscle Fatigue","Cardiovascular Adaptation","Non-Pharmacological Treatment","Hypertension Prevention","Autonomic Nervous System","2025-05-15",{"date":348,"type":31},"2025-05-16",{"date":350,"type":31},"2025-04-21",{"date":352,"type":22},"2025-09",{"name":354,"class":38},"Canterbury Christ Church University"]